Jimmy Fund Press Releases
Dana-Farber Cancer Institute is awarded its fourth consecutive designation as a Magnet® organization for excellence in nursing practice and patient careAugust 20, 2019
Dana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time.
Scientists have found a rare, inherited gene mutation that raises the risk of pancreatic cancer and other malignancies.
Dana-Farber/Brigham and Women’s Cancer Center has been ranked by U.S. News & World Report as the best for cancer care in New England for the 19th straight year.
High doses of 60-plus year-old chemotherapy drug found to spur immune system attack on lymphoma.
U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new Best Children’s Hospitals rankings.
Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer.
U.S. District Court rules Dana-Farber scientist is an inventor on six critical immunotherapy patentsMay 17, 2019
Dana-Farber scientist, Gordon Freeman, PhD, is a co-inventor on six critical immunotherapy patents.
Targeted therapy proves effective against aggressive rare blood cancer. The clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.
T-Mobile CEO John Legere visited Dana-Farber on Wednesday to present a $4.5 million check to support the Profile initiative. True to his word, Legere was sporting magenta colored hair.
First-of-its-kind treatment beats back notorious brain tumor. For 25-year-old Kristina Johnson, "It’s letting me live my life the way I want to.”
Dana-Farber/Brigham and Women's Cancer Center announced the launch of the Young-Onset Colorectal Cancer Center. It is among the first centers in the country.
Boston magazine has named more than 115 physicians and surgeons affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide.